Exclusive-AbbVie nears roughly $8 billion deal for drug developer Cerevel-sources
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/13/2026
- S&P 500 ends higher as strong inflation data cements rate-hike bets
- Oracle raises full year profit guidance, stock rises after hours
- Oil falls but head for 8% weekly gain on tight supply; US diesel hits record
- 'No panic anywhere' may be the problem, BofA strategists warn
- Buy Shopify stock at this ’AI-enabled entry point,’ analyst says
- After-Hours Movers: ORCL, CRWV, ADBE, ACVA, CPRT, ZUMZ, PMTS, RH
- After-Hours Movers: COO, AEO, NAVN, AVAV, TORO
- After-Hours Movers: LULU, IOT, PATH, DOCU, ASAN, GWRE, ZS, PL, SWBI, OXM
- After-Hours Movers: AVGO, SNOW, HPE, NTAP, NTSK, CHPT, FIVE, TLYS, PVH, RARE
- After-Hours Movers: DELL, PANW, GTLB, CRDO, MDB, HPE, SMCI
AbbVie (ABBV) to acquire Cerevel (CERE) for $8.7 billion; deal 'makes sense' says analyst
December 6, 2023 5:30 PM EST(Updated - December 7, 2023 5:18 AM EST)
AbbVie Inc. (NYSE: ABBV) announced it will acquire Cerevel Therapeutics (NASDAQ: CERE) in a deal that will the former acquire the latter's robust neuroscience pipeline of multiple clinical-stage and preclinical candidates.
The acquisition enhances AbbVie's neuroscience lineup by introducing a diverse array of potentially superior assets. Assets with the potential to revolutionize treatment standards for psychiatric... More
AbbVie (ABBV) to Acquire Cerevel Therapeutics (CERE) for $45 Per Share, $8.7 Billion Deal
December 6, 2023 4:31 PM ESTAbbVie Inc. (NYSE: ABBV) and Cerevel Therapeutics (NASDAQ: CERE) today announced a definitive agreement under which AbbVie will acquire Cerevel Therapeutics and its robust neuroscience pipeline of multiple clinical-stage and preclinical candidates with potential across several diseases including schizophrenia, Parkinson's disease (PD), and mood disorders. The acquisition complements AbbVie's neuroscience portfolio, adding a wide range of potentially best-in-class assets that may transform standards of care across... More
Cerevel Therapeutics (CERE) Halted, News Pending
December 6, 2023 4:29 PM ESTCerevel Therapeutics (NASDAQ: CERE) Halted, News Pending
